Late Breaking Abstract - Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy - Vienna 2024

Advances in clinical practice for rare interstitial lung diseases: from research to the real world

Chair(s): Pilar Rivera Ortega, Cormac McCarthy

Session type: Oral presentation

Late Breaking Abstract - Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy

Sydney B. Montesi

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy

Sydney B. Montesi

Replay

Poster

Abstract

Slides

Inhaled GM-CSF Reduces the Need for Whole Lung Lavage (WLL) and Improves Gas Exchange in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients

Ilaria Campo

Replay

Poster

Abstract

Slides

DIPNECH: An International Case Series

Marissa O'callaghan

Replay

Abstract

Slides

Comparison of clinical and radiological features of lung involvement between IgG4-related disease and idiopathic multicentric Castleman disease

Jiamin Zhou

Replay

Poster

Abstract

Slides

Characteristics and clinical course of lymphangioleiomyomatosis (LAM) in patients treated with sirolimus in France

Vincent Cottin

Replay

Poster

Abstract

Slides

Machine Learning to Identify Novel Serum Biomarkers in Lymphangioleiomyomatosis

Nicholas Mc Carthy

Replay

Abstract

Slides

French cohort RADICO-ILD2 (FIFA): Asymptomatic manifestations in relatives of patients carrying telomere-related gene variants

Rapha Borie

Replay

Poster

Abstract

Slides

From body composition to pulmonary fat attenuation volume: evaluation of new CT-based biomarkers to predict the overall survival in patients with non-specific interstitial pneumonia (NSIP).

Francesco Bonella

Replay

Poster

Abstract

Slides

Childrens ILDs survivors in adulthood: a European Study

Effrosyni D. Manali

Replay

Poster

Abstract

Slides

Nintedanib in children and adolescents with fibrosing ILDs: interim analysis of InPedILD-ON

Matthias Griese

Replay

Poster

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}